Use of Bone-Modifying Agents in Australian Men with Castration-Resistant Prostate Cancer (CRPC)

被引：0
|
作者：
Anton, Angelyn [1 ]
Parente, Phillip [2 ,3 ]
Azad, Arun [4 ]
Weickhardt, Andrew [5 ]
Wong, Shirley [6 ]
Shapiro, Julia [3 ]
Torres, Javier [7 ]
Parnis, Francis [8 ]
Semira, Christine [1 ]
Gibbs, Peter [1 ,6 ]
Tran, Ben [1 ,9 ]
Pezaro, Carmel [2 ,3 ]
机构：
[1] Walter & Eliza Hall Inst Med Res, Melbourne, Vic, Australia
[2] Eastern Hlth, Melbourne, Vic, Australia
[3] Monash Univ, Melbourne, Vic, Australia
[4] Monash Hlth, Melbourne, Vic, Australia
[5] Olivia Newton John Canc Wellness & Res Ctr, Melbourne, Vic, Australia
[6] Western Hlth, Melbourne, Vic, Australia
[7] Goulburn Valley Hlth, Melbourne, Vic, Australia
[8] Adelaide Canc Ctr, Adelaide, SA, Australia
[9] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
abs100
引用
收藏
页码：32 / 32
页数：1
相关论文
共 50 条
  • [1] Bone modifying agents in veterans with castration-resistant prostate cancer.
    Bauman, Jordan
    Kumbier, Kyle
    Burns, Jennifer A.
    Sparks, Jordan
    Tsao, Phoebe A.
    Skolarus, Ted A.
    Shahinian, Vahakn B.
    Caram, Megan Veresh
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Castration-resistant prostate cancer (CRPC)
    Loidl, W.
    Luger, F.
    Roosen, A.
    UROLOGE, 2014, 53 (03): : 391 - 399
  • [3] Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
    Aaron P. Mitchell
    Akriti Mishra Meza
    Katherine S. Panageas
    Allison Lipitz-Snyderman
    Azeez Farooki
    Michael J. Morris
    Prostate Cancer and Prostatic Diseases, 2023, 26 : 126 - 132
  • [4] Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
    Mitchell, Aaron P.
    Meza, Akriti Mishra
    Panageas, Katherine S.
    Lipitz-Snyderman, Allison
    Farooki, Azeez
    Morris, Michael J.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2023, 26 (01) : 126 - 132
  • [5] Examining skeletal-related events in Australian men with castration-resistant prostate cancer (CRPC)
    Anton, A.
    Wong, S.
    Parente, P.
    Azad, A.
    Shapiro, J. A.
    Weickhardt, A.
    Torres, J.
    Parnis, F.
    Goh, J.
    Semira, C.
    Gibbs, P.
    Tran, B.
    Pezaro, C.
    ANNALS OF ONCOLOGY, 2018, 29 : 70 - 70
  • [6] Denosumab in men with nonmetastatic castration-resistant prostate cancer (CRPC) at high risk for bone metastases
    Smith, M. R.
    Fizazi, K.
    Miller, K.
    Egerdie, B.
    Morote, J.
    Tammela, T. L.
    Wong, S.
    Ye, Z.
    Braun, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S682 - S682
  • [7] Clinical factors associated with prescribing patterns of bone modifying agents in men with metastatic castration-resistant prostate cancer
    Kobe, Christopher
    Nguyen, Charles B.
    Kumbier, Kyle E.
    Bauman, Jordan
    Burns, Jennifer A.
    Tsao, Phoebe A.
    Sparks, Jordan B.
    Caram, Megan Veresh
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] ARN-509 IN MEN WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Rathkopf, D.
    Antonarakis, E. S.
    Shore, N. D.
    Tutrone, R.
    Alumkal, J.
    Ryan, C. J.
    Saleh, M.
    Hauke, R.
    Chow-Maneval, E.
    Scher, H. I.
    ANNALS OF ONCOLOGY, 2012, 23 : 317 - 317
  • [9] Bisphosphonate utilization among men with metastatic castration-resistant prostate cancer (CRPC).
    Morgans, Alicia Katherine
    Graves, Amy J.
    Penson, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Castration-resistant prostate cancer (CRPC) [Kastrationsrefraktäres prostatakarzinom (CRPC)]
    Loidl W.
    Luger F.
    Roosen A.
    Der Urologe, 2014, 53 (3): : 391 - 401
12345